3-(1,4-Dioxaspiro[4.5]decan-8-ylidene)propan-1-ol | 960370-93-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-(1,4-Dioxaspiro[4.5]decan-8-ylidene)propan-1-ol
• 英文别名: 3-(1,4-dioxaspiro[4.5]decan-8-ylidene)propan-1-ol
• CAS: 960370-93-8
• 化学式: C₁₁H₁₈O₃
• 分子量: 198.262
• InChiKey: BFSZROWAUVQXIX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(1,4-Dioxaspiro[4.5]decan-8-ylidene)propan-1-ol 、 三氟甲磺酸酐 在 2,4,6-三甲基吡啶 作用下， 以 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  Optimization of novel di-substituted cyclohexylbenzamide derivatives as potent 11β-HSD1 inhibitors

  摘要：

  Novel 4,4-disubstituted cyclohexylbenzamide inhibitors of 11beta-HSD1 were optimized to account for liabilities relating to in vitro pharmacokinetics, cytotoxicity and protein-related shifts in potency. A representative compound showing favorable in vivo pharmacokinetics was found to be an efficacious inhibitor of 11beta-HSD1 in a rat pharmacodynamic model (ED(50)=10mg/kg).

  DOI：

  10.1016/j.bmcl.2009.01.026
• 作为产物：
  描述：

  8-[3-(benzyloxy)propylidene]-1,4-dioxaspiro[4.5]decane 在 氨 、 水 、 sodium 作用下， 以 乙醚 、 乙醇 为溶剂， 生成 3-(1,4-Dioxaspiro[4.5]decan-8-ylidene)propan-1-ol
  参考文献：
  名称：

  Benzamide derivatives and uses related thereto

  摘要：

  公式I的苯甲酰胺衍生物已被描述，并具有治疗效用，特别是在治疗糖尿病、肥胖和相关疾病和紊乱方面：其中R1、R2、R3、R4、R5、R6、R7、R8和n如本文所定义。

  公开号：

  US20070299080A1

文献信息

• Benzamide derivatives and uses related thereto
  申请人：Powers P. Jay

  公开号：US20070299080A1

  公开（公告）日：2007-12-27

  Benzamide derivatives of formula I are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and n are as defined herein.

  公式I的苯甲酰胺衍生物已被描述，并具有治疗效用，特别是在治疗糖尿病、肥胖和相关疾病和紊乱方面：其中R1、R2、R3、R4、R5、R6、R7、R8和n如本文所定义。
• Optimization of novel di-substituted cyclohexylbenzamide derivatives as potent 11β-HSD1 inhibitors
  作者：Dustin L. McMinn、Yosup Rew、Athena Sudom、Seb Caille、Michael DeGraffenreid、Xiao He、Randall Hungate、Ben Jiang、Juan Jaen、Lisa D. Julian、Jacob Kaizerman、Perry Novak、Daqing Sun、Hua Tu、Stefania Ursu、Nigel P.C. Walker、Xuelei Yan、Qiuping Ye、Zhulun Wang、Jay P. Powers

  DOI：10.1016/j.bmcl.2009.01.026

  日期：2009.3

  Novel 4,4-disubstituted cyclohexylbenzamide inhibitors of 11beta-HSD1 were optimized to account for liabilities relating to in vitro pharmacokinetics, cytotoxicity and protein-related shifts in potency. A representative compound showing favorable in vivo pharmacokinetics was found to be an efficacious inhibitor of 11beta-HSD1 in a rat pharmacodynamic model (ED(50)=10mg/kg).